The $750 Threshold: SAMHSA Makes Contingency Management Economically Viable
- SAMHSA raised the contingency management (CM) incentive cap from $75 to $750 per patient per year — a 10x increase
- CM is now the only evidence-based behavioral intervention for stimulant use disorder; no FDA-approved medications exist for this condition
- The new cap applies to all State Opioid Response (SOR) and Tribal Opioid Response (TOR) grant-funded programs
- Digital CM delivery platforms (e.g., Pelago, DynamiCare) can now scale programs that were previously economically unviable at $75/year
For years, contingency management occupied an awkward position in addiction treatment. The evidence was strong — meta-analyses consistently showed CM outperforming other behavioral interventions for stimulant use disorders. But the implementation was strangled by a cap so low it rendered programs impractical. At $75 per patient per year, clinics could barely afford the administrative overhead of running a CM program, let alone deliver meaningful incentives.
A Cap That Killed the Intervention
The original $75 limit was set decades ago and never adjusted for inflation or clinical reality. Programs that tried to operate under this constraint reported two consistent problems: incentive amounts too small to motivate behavior change, and administrative costs that exceeded the therapeutic budget. Many clinics simply stopped offering CM. The intervention with the strongest evidence base for stimulant addiction became the one least available in practice.
The 10x increase to $750 changes the arithmetic entirely. A program can now offer weekly incentives of $14-15 over a year-long treatment course — enough to implement the escalating reinforcement schedules that clinical trials actually used when demonstrating CM's efficacy.
Why This Matters Now
The timing is not accidental. Stimulant-related overdose deaths have surged alongside the fentanyl crisis, with methamphetamine and cocaine increasingly contaminated with synthetic opioids. Yet while buprenorphine and methadone address opioid dependence, clinicians treating stimulant use disorder have had no pharmacological tools. CM was their only evidence-based option — and it was functionally defunded.
The new cap applies specifically to SOR and TOR grants, which fund the majority of community-based addiction treatment in the United States. This means the programs with the highest-need populations are the first to benefit. SAMHSA has also explicitly endorsed digital CM platforms, which use smartphone-based verification (photo or video confirmation of negative drug tests) to reduce clinic burden and expand geographic reach.
What Clinicians Should Do
For practitioners treating stimulant use disorder: check whether your program or affiliated clinic receives SOR/TOR funding. If so, CM implementation is now both funded and practical. Digital platforms like DynamiCare and Pelago handle the logistics — randomized incentive delivery, verification, and reporting. The National Drug Control Strategy now explicitly recommends CM, which provides additional institutional backing for program development proposals.
The clinical takeaway is concrete: if you treat stimulant addiction and have not yet implemented contingency management, the last remaining excuse — inadequate funding — has been removed.
The intervention with the strongest evidence base for stimulant addiction was the one least available in practice. A 10x funding increase changes that equation overnight.
The $750 cap applies only to SAMHSA SOR/TOR grants, not to all federally funded or private programs. Medicaid reimbursement for CM remains inconsistent across states, and some jurisdictions still classify incentive payments as problematic under anti-kickback statutes.